Skip to content

High intensity focused ultrasound( HIFU) combined with dual drug chemotherapy is used for second-line and above treatment of advanced intrahepatic cholangiocarcinoma: A prospective, single-arm, single-center phase?/? clinical study

High intensity focused ultrasound( HIFU) combined with dual drug chemotherapy is used for second-line and above treatment of advanced intrahepatic cholangiocarcinoma: A prospective, single-arm, single-center phase?/? clinical study

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200064450
Enrollment
Unknown
Registered
2022-10-09
Start date
2022-10-08
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intrahepatic cholangiocarcinoma

Interventions

experimental group:high intensity focused ultrasound

Sponsors

Mianyang Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years; 2. The histopathological diagnosis of intrahepatic cholangiocarcinoma was confirmed as advanced intrahepatic cholangiocarcinoma by imaging; 3. After first-line treatment failed, two-drug regimen chemotherapy was proposed for second-line and above treatment after MDT discussion; 4. ECOG PS score 0-2; 5. At least >=1 additional discontinuous lesion was monitored; 6. No absolute contraindication of chemotherapy; 7. Expected survival >12 weeks.

Exclusion criteria

Exclusion criteria: 1. Patients with no HIFU for ablation; 2. Serious heart, lung and kidney diseases, unable to complete treatment; 3. Terminally ill patients who give up treatment requirements; 4. Unable to cooperate with treatment; 5. The skin pain response of the expected treatment pathway is dull and lost.

Design outcomes

Primary

MeasureTime frame
Progression-free survival;

Secondary

MeasureTime frame
Disease control rate;Objective response rate;Overall survival;

Countries

China

Contacts

Public ContactFeng Gang

Mianyang Central Hospital

fenggangmych@sina.com+86 18141380968

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026